Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 270Stomach Neoplasms 200Rectal Neoplasms 180Pancreatic Neoplasms 131Colonic Neoplasms 112Neoplasm Metastasis 74Esophageal Neoplasms 63Carcinoma, Hepatocellular 41Neoplasms 40Cholangiocarcinoma 36Adenocarcinoma Of Esophagus 32Adenocarcinoma 32Biliary Tract Neoplasms 25Liver Neoplasms 21Gallbladder Neoplasms 21Recurrence 18Gastrointestinal Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Peritoneal Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Esophageal Squamous Cell Carcinoma 14Locally Advanced Rectal Cancer 12Bile Duct Neoplasms 11Colorectal Cancer Metastatic 8Unspecified Adult Solid Tumor, Protocol Specific 7Ovarian Neoplasms 7Lymphoma, Extranodal NK-T-Cell 7Head and Neck Neoplasms 7Appendiceal Neoplasms 7

Interventions

tislelizumab 2disitamab vedotin 2Trastuzumab 2Tegafur 2S 1 (combination) 1Oxaliplatin 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Gastric Cancer × Oxaliplatin × Clear all
NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡